Investment Rating - The industry is rated as "Positive" with expectations of overall returns exceeding the CSI 300 Index by more than 5% in the next six months [23]. Core Insights - The report emphasizes a dual approach of "short-term stimulus + long-term mechanisms" to support the restaurant, tourism, and education sectors, highlighting the importance of quality upgrades, community penetration, high-end and international development, and resource equity in education [21][15]. - The report identifies potential growth opportunities in the consumer services sector driven by government policies aimed at enhancing service quality and expanding market access [21]. Summary by Sections 1. Restaurant Policies - The government aims to enhance the quality of restaurant services and support local specialty dining, which will drive the industry towards high-end and differentiated development [2][3]. - The improvement of community dining options is expected to increase consumer convenience and efficiency, particularly in urban areas [3]. 2. Tourism Policies - Policies are set to expand cultural and tourism consumption by supporting scenic spots and cultural institutions to diversify service offerings and extend operating hours [4][7]. - The focus on winter tourism aims to transition seasonal activities into year-round opportunities, enhancing economic benefits in resource-rich regions [7]. 3. Education Policies - The government plans to increase educational resources in urban areas to accommodate the influx of school-age children, which will alleviate enrollment pressures and enhance consumer spending in related sectors [12][13]. - Financial support measures, such as increased student aid and loan policies, are expected to reduce the financial burden on families and stimulate consumption [15]. 4. New Consumption Models - The promotion of new high-end consumption models, such as low-altitude tourism and cruise services, is anticipated to cater to the needs of higher-income groups and stimulate rural economies through initiatives like the homestay economy [10][11]. 5. Policy Synergies and Industry Opportunities - The report highlights the importance of optimizing the consumption environment and providing financial support to enhance investment in the restaurant and tourism sectors [18][19]. - The potential for population mobility and consumption linkage is noted, with educational resource optimization likely to drive urbanization and related consumer spending [20].

2025 年 03 月 17 日 行业周报 看好/首次 石油石化 石化周报（3/10-3/17）：海外天然气价格明显增长 ◼ 走势比较 (20%) (12%) (4%) 4% 12% 20% 24/3/18 24/5/29 24/8/9 24/10/20 24/12/31 25/3/13 相关研究报告 证券分析师：白竣天 E-MAIL：baijt@tpyzq.com 分析师登记编号：S1190522110001 证券分析师：王亮 E-MAIL：wangl@tpyzq.com 分析师登记编号：S1190522120001 报告摘要 1.重点行业和产品情况跟踪 受拉尼娜及欧美天然气消费量增长影响，天然气价格反季节上 涨。2025 年以来欧盟天然气消费量同比增长 38.66%，欧盟天然气库存 同比下降 39.27%，并且 2025 年以来美国天然气表观消费量也同比增 长 18.5%，使得美国和欧洲天然气价格明显增长。本周国内 LNG 出厂 价格指数为 4557 元/吨，比上周下降 3.06%，比去年同期增长 8.68%。 本周 NYMEX 天然气期货价格为 4.09 美元/百万英热单位，比上周下降 1.82%，比去 ...

[Table_Author] 证券分析师：刘晓锋 电话：13401163428 E-MAIL：liuxf@tpyzq.com 执业资格证书编码：S1190522090001 研究助理：孙弋轩 黄金持续上涨，商品基金录得较大涨幅 金融工程周报 大类资产与基金周报（20250310-20250314）—— 电话：18910596766 E-MAIL：sunyixuan@tpyzq.com 一般证券业务登记编码：S1190123080008 内容摘要 太 平 洋 证 券 股 份 有 限 公 司 证 券 研 究 报 告 请务必阅读正文之后的免责条款部分 守正 出奇 宁静 致远 [Table_Title] [Table_Summary] [Table_Message]2025-03-16 金 融 工 程 周 报 ◼ 大类资产市场概况：1）权益：本周 A 股市场中上证指数收盘 3419.56，涨跌幅 1.39%， 深证成指、中小板指数、创业板指、上证 50、沪深 300、中证 500、中证 1000、中证 2000、 北证 50 涨跌幅分别为 1.24%、1.22%、0.97%、2.18%、1.59%、1.43%、0.9 ...

2025 年 03 月 17 日 行业周报 看好/维持 计算机 计算机 AI 国产化趋势延续 ◼ 走势比较 (30%) (14%) 2% 18% 34% 50% 24/3/18 24/5/29 24/8/9 24/10/20 24/12/31 25/3/13 计算机 沪深300 相关研究报告 <<通用型 AI Agent 更近一步，AI 应 用蓄势待发>>--2025-03-10 <<数字虚拟商品综合服务商，发力云 终端打造第二成长曲线>>--2025- 03-10 <<业绩持续高增，合同负债及存货大 幅增长>>--2025-03-04 证券分析师：曹佩 电话： E-MAIL：caopeisz@tpyzq.com 分析师登记编号：S1190520080001 证券分析师：王景宜 电话： E-MAIL：wangjy@tpyzq.com 分析师登记编号：S1190523090002 报告摘要 OpenAI 打压 DeepSeek，AI 竞争已上升至国家层面。3 月 13 日，OpenAI 向美国政府提交提案，呼吁禁用 DeepSeek 及其他中国 AI 模型，并采取一 系列措施打压中国 AI 发展。提案主要指控 ...

证券研究助理：徐梓铭 2025 年 03 月 16 日 投资策略 行胜于言 核心观点：国内正着手对长期痛点进行政策解决，而美国正在经历 "排毒"期和贸易不确定性的困扰。无论长期的结果究竟如何，请暂时对 东升西落的叙事多点信心，盘面已经做出积极反应，技术面风险可控，大 市值绩优股胜率和赔率更佳。 国内：经济长期痛点的政策推进+降准降息的宽松预期=东升预期的 强化 证券分析师：张冬冬 E-MAIL：zhangdd@tpyzq.com 分析师登记编号：S1190522040001 E-MAIL：xuzm@tpyzq.com 一般证券从业编号：S1190123050005 证券分析师：吴步升 E-MAIL：wubs@tpyzq.com 分析师登记编号：S1190524110002 政策对长期痛点的着手解决：1）人口：《政府工作报告》首次提出发 放育儿补贴，呼和浩特补贴力度空前的示范效应——市场未来可想象的空 间大，力度足。2）消费：《政府工作报告》第一大任务——大力提振消费、 提高投资效益，全方位扩大国内需求。3 月 14 日最高法和国家金融监管 总局分别从法律和金融两方面对消费落地政策支持，市场反应积极。3 月 1 ...

Investment Rating - The report maintains a "Buy" rating for Prolo Pharmaceutical (000739) [1] Core Views - Prolo Pharmaceutical is accelerating its integrated layout of raw materials and formulations, with CDMO expected to enter a new inflation era [1] - The company has established a 2030 development strategy focusing on refining raw materials, strengthening CDMO, enhancing pharmaceuticals, and expanding into medical aesthetics [4][19] - The company has demonstrated long-term development confidence through stock buybacks, with a total repurchase amount of 1.53 billion yuan planned for cancellation [4][23] Summary by Sections Company Overview - Prolo Pharmaceutical, founded in 1989 and listed in 2001, is a leading pharmaceutical manufacturer in China, focusing on raw materials, CDMO, pharmaceuticals, and medical aesthetics [18] - The company has undergone significant strategic adjustments since 2017, implementing a unified management model and achieving its strategic goals by 2023 [19] Raw Material and Medical Aesthetics Business - The company is a leading domestic player in specialty raw materials, with a focus on oral cephalosporins, penicillins, and veterinary raw materials [5] - Prolo has increased the number of API projects significantly, with plans to add 30-50 new DMFs in the next 3-5 years [5] CDMO Business Outlook - The CDMO sector is expected to enter a new inflation era, driven by supportive policies for innovative drugs and a significant increase in project numbers [6][8] - The company has seen a 42% year-on-year increase in projects, indicating a robust growth trajectory for its CDMO business [8] Revenue Growth and Business Segmentation - Prolo's revenue has grown from 78.80 billion yuan in 2020 to an estimated 120.22 billion yuan in 2024, with a compound annual growth rate (CAGR) of 11.14% [32] - The revenue contribution from CDMO and formulation businesses has increased, with CDMO revenue growing at a CAGR of 15.60% from 2020 to 2024 [34] Profitability and Financial Metrics - The company's gross margin has decreased from 27.96% in 2020 to 23.85% in 2024, while the net margin has also declined [38] - Despite the decline in margins, the company continues to invest in R&D, with R&D expenses increasing from 4.44% to 5.34% of total revenue [38]

2025-03-16 行业周报 看好/维持 航空航天与国防Ⅲ 工业资本货物 军工行业周报(2025.03.10-2025.03.16)：中伊俄举行"安全纽带-2025"联合演习 走势比较 中伊俄举行"安全纽带-2025"联合演习 3 月 11 日，随着参加中伊俄"安全纽带-2025"联合演习的舰艇 靠泊伊朗恰巴哈尔港，此次联演海上演习阶段圆满结束。此次联演以 "共创和平与安全"为主题，于 3 月 9 日拉开帷幕，分为集结准备、 海上演习、港岸总结三个阶段举行，旨在深化各参演国家军队之间的 军事互信和务实合作。中方参演兵力为海军第 47 批护航编队的导弹 驱逐舰包头舰、综合补给舰高邮湖舰。海上演习于 3 月 10 日至 11 日 在恰巴哈尔港附近海域组织实施，主要围绕打击海上目标、临检拿 捕、损害管制、联合搜救等展开演练。 行业观点： -20% -10% 0% 10% 20% 30% 40% 50% Mar/24 Apr/24 May/24 Jun/24 Jul/24 Aug/24 Sep/24 Oct/24 Nov/24 Dec/24 Jan/25 Feb/25 航空航天与国防 沪深300 推荐公司及评级 相 ...

2025 年 03 月 16 日 公司点评 增持/维持 股票回购彰显长期发展信心，产能投放有望驱动收入快速增长 走势比较 (30%) (18%) (6%) 6% 18% 30% 24/3/15 24/5/26 24/8/6 24/10/17 24/12/28 25/3/10 股票数据 | 总股本/流通(亿股) | 1.15/0.77 | | --- | --- | | 总市值/流通(亿元) | 22.66/15.07 | | 12 个月内最高/最低价 | 23.8/13.43 | | (元) | | 相关研究报告 <>--2025-01-19 <>--2024-10-25 <>-- 2024-08-29 证券分析师：周豫 共同药业(300966) 昨收盘:19.66 E-MAIL：zhouyua@tpyzq.com 分析师登记编号：S1190523060002 证券分析师：乔露阳 E-MAIL：qiaoly@tpyzq.com 分析师登记编号：S1190524080001 事件 2025 年 2 月 25 日，公司发布股票回购预案，公司拟以集中竞价交易 方式回购股份，回购金额在 2,000 万元到 3,000 ...

Investment Rating - The report maintains a "Buy" rating for Prolo Pharmaceutical (000739) [1] Core Views - Prolo Pharmaceutical is accelerating its integrated layout of raw materials and formulations, with CDMO expected to enter a new inflation era [1] - The company has established a 2030 development strategy focusing on refining raw materials, strengthening CDMO, enhancing pharmaceuticals, and expanding into medical beauty [4][19] - The company has demonstrated long-term development confidence through stock buybacks, with a total repurchase amount of 1.53 billion yuan planned for cancellation [4][23] Summary by Sections Company Overview - Prolo Pharmaceutical, founded in 1989 and listed in 2001, is a leading pharmaceutical manufacturer in China, focusing on raw materials, CDMO, pharmaceuticals, and medical beauty products [18] - The company has seven raw material production plants and two formulation plants, with a complete industrial chain from intermediates to sales channels [18][19] Raw Material and Medical Beauty Business - The company is a leading domestic player in specialty raw materials, with significant market positions in oral cephalosporins and other key products [5] - Prolo has increased the number of API projects significantly, with plans to add 30-50 new DMFs in the next 3-5 years [5] - The medical beauty division is expanding, focusing on cosmetic raw materials and collagen products, with future plans for botulinum toxin [5] CDMO Business Outlook - The CDMO sector is expected to enter a new inflation era, driven by supportive policies for innovative drugs and a significant increase in project numbers [6][8] - The company has seen a 42% year-on-year increase in projects, indicating a strong growth trajectory for its CDMO business [8] Revenue Growth and Business Segmentation - Prolo's revenue has grown from 78.80 billion yuan in 2020 to an estimated 120.22 billion yuan in 2024, with a compound annual growth rate (CAGR) of 11.14% [32] - The revenue contribution from CDMO and formulation businesses is increasing, with CDMO revenue growing at a CAGR of 15.60% from 2020 to 2024 [34] Financial Projections - The company forecasts revenues of 130.58 billion yuan, 143.93 billion yuan, and 159.58 billion yuan for 2025, 2026, and 2027, respectively, with corresponding net profits of 11.53 billion yuan, 13.24 billion yuan, and 15.48 billion yuan [10][12]

2025 年 03 月 15 日 公司点评 增持/维持 粤高速 A(000429) 目标价: 昨收盘:13.29 粤高速 A，2024 年报点评，业绩承压，迎来管养费政策曙光 ◼ 走势比较 近日，粤高速 A 披露 2024 年报。本报告期，实现营业总收入 45.7 亿，同比减-6.34%；归母净利 15.62 亿，同比减-4.39%；扣非的归母 净利 16.45 亿，同比减-3.55%；基本每股收益 0.75 元，加权 ROE 为 15.52%，经营活动产生的现金流量净额为 32.56 亿元。 分红政策，公司拟每 10 股派发股息 5.23 元（含税），合计拟派发 股利 10.9 亿，占 24 年归母净利润的 70%。若以年报披露日计算的股 息率约为 3.59%。 ■ 点评 (20%) (2%) 16% 34% 52% 70% 24/3/14 24/5/26 24/8/7 24/10/19 24/12/31 25/3/14 粤高速A 沪深300 ◼ 股票数据 总股本/流通(亿股) 20.91/13.03 总市值/流通(亿元) 277.87/173.21 12 个月内最高/最低价 (元) 14.98/9.46 ...